Diamyd Medical

Diamyd Medical AB (omx: SSE18765 DIAM B) is a Swedish medical research company, listed on the Stockholm Stock Exchange. Diamyd's research utilises two different platform technologies. One is based on the GAD65 molecule, which is used in a vaccine that has proven effective in delaying the destruction of beta cells associated with type 1 diabetes. The use of GAD65 for therapeutic purposes is licensed from the University of California, Los Angeles. In December, 2007 Diamyd submitted the application for a phase III trial in the United States to the FDA. The company will perform a parallell phase III trial in Europe.

The other technology is a viral delivery system of proteins to nervous tissue (Nerve Targeted Drug Delivery System, NTDDS) that can be used e.g. against chronic pain. The company is based in Stockholm, Sweden with a subsidiary in Pittsburgh, Pennsylvania.